- Home
- HAE
as 07-26-2024 4:00pm EST
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
| Founded: | 1971 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 4.5B | IPO Year: | 1991 |
| Target Price: | $109.50 | AVG Volume (30 days): | 438.5K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.29 | EPS Growth: | 2.23 |
| 52 Week Low/High: | $70.74 - $97.97 | Next Earning Date: | 08-08-2024 |
| Revenue: | $1,309,055,000 | Revenue Growth: | 12.01% |
| Revenue Growth (this year): | 8.02% | Revenue Growth (next year): | 5.37% |
Stock Insider Trading Activity of Haemonetics Corporation (HAE)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lingamneni Anila | HAE | EVP, Chief Technology Officer | Jul 11 '24 | Sell | $90.00 | 2,136 | $192,240.00 | 21,410 | SEC Form 4 |
| Lingamneni Anila | HAE | EVP, Chief Technology Officer | Jul 11 '24 | Sell | $90.00 | 79 | $7,110.00 | 21,331 | SEC Form 4 |
| Basil Michelle L | HAE | EVP and General Counsel | May 28 '24 | Sell | $87.86 | 8,896 | $781,602.56 | 35,351 | SEC Form 4 |
| Basil Michelle L | HAE | EVP and General Counsel | May 28 '24 | Sell | $88.57 | 4,094 | $362,605.58 | 31,257 | SEC Form 4 |
| Strong Stewart W | HAE | President, Global Hospital | May 28 '24 | Sell | $87.53 | 8,857 | $775,253.21 | 18,196 | SEC Form 4 |
| Basil Michelle L | HAE | EVP and General Counsel | May 17 '24 | Sell | $95.00 | 1,073 | $101,935.00 | 29,352 | SEC Form 4 |
| Basil Michelle L | HAE | EVP and General Counsel | May 17 '24 | Sell | $95.08 | 1,604 | $152,508.32 | 31,257 | SEC Form 4 |
| Strong Stewart W | HAE | President, Global Hospital | May 17 '24 | Sell | $95.11 | 686 | $65,245.46 | 18,196 | SEC Form 4 |
| Llorens Josep | HAE | EVP, Global Manufacturing | May 17 '24 | Sell | $94.82 | 822 | $77,942.04 | 16,350 | SEC Form 4 |
| Llorens Josep | HAE | EVP, Global Manufacturing | May 17 '24 | Sell | $95.08 | 987 | $93,843.96 | 21,310 | SEC Form 4 |
| Llorens Josep | HAE | EVP, Global Manufacturing | May 15 '24 | Sell | $96.14 | 770 | $74,027.80 | 17,172 | SEC Form 4 |
| Strong Stewart W | HAE | President, Global Hospital | May 15 '24 | Sell | $96.04 | 733 | $70,397.32 | 15,608 | SEC Form 4 |
| Basil Michelle L | HAE | EVP and General Counsel | May 15 '24 | Sell | $96.14 | 985 | $94,697.90 | 30,425 | SEC Form 4 |
| Lingamneni Anila | HAE | EVP, Chief Technology Officer | May 6 '24 | Sell | $95.00 | 2,305 | $218,975.00 | 12,295 | SEC Form 4 |
Latest Haemonetics Corporation News
HAE Breaking Stock News: Dive into HAE Ticker-Specific Updates for Smart Investing
Zacks
8 hours ago
Hologic (HOLX) Buys Endomag to Boost Breast Cancer Solutions
Zacks
11 hours ago
ICON (ICLR) Q2 Earnings Surpass Estimates, Margins Expand
Zacks
a day ago
Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms
Zacks
a day ago
Align Technology (ALGN) Beats on Q2 Earnings, Lowers '24 Sales View
Zacks
2 days ago
Boston Scientific (BSX) Q2 Earnings Beat, Organic Sales Rise
Zacks
2 days ago
Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View
Zacks
2 days ago
AtriCure (ATRC) Gains China Approval for AtriClip LAA System
Argus Research
3 days ago
HAE: What does Argus have to say about HAE?
Compare HAE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HAE Haemonetics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.